Tianjin, China

Chenhui Wen

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ningxia Eppen Biotech Co., Ltd. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chenhui Wen: Innovator in Gene Engineering

Introduction

Chenhui Wen is a prominent inventor based in Tianjin, China. He has made significant contributions to the field of biotechnology, particularly in gene engineering. His innovative work has led to the development of a unique patent that showcases his expertise and dedication to advancing scientific knowledge.

Latest Patents

Chenhui Wen holds a patent titled "Gene Engineering Bacteria for Producing L-Arginine and Construction Method and Application of Gene Engineering Bacteria." This patent highlights his work in creating genetically engineered bacteria that can efficiently produce L-arginine, an important amino acid with various applications in health and nutrition. He has 1 patent to his name, reflecting his commitment to innovation in biotechnology.

Career Highlights

Wen is currently employed at Ningxia Eppen Biotech Co., Ltd., where he continues to push the boundaries of gene engineering. His role at the company allows him to collaborate with other talented professionals in the field, further enhancing his contributions to biotechnology.

Collaborations

Chenhui Wen has worked alongside notable colleagues such as Shuai Jiang and Yining Liu. Their collaborative efforts have fostered an environment of innovation and creativity, leading to advancements in their respective areas of expertise.

Conclusion

Chenhui Wen is a dedicated inventor whose work in gene engineering has the potential to impact various industries. His innovative patent and collaborations with talented professionals underscore his commitment to advancing biotechnology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…